Avalyn
Seattle, Washington, United States · Biotechnology, Healthcare, Health Care
Avalyn is reimagining the future of pulmonary fibrosis treatment, with a pipeline of new inhaled formulations of approved medicines. Unlike currently available oral therapies, our inhaled approach allows us to tackle the underlying pathophysiology of pulmonary fibrosis at its source by safely delivering treatments directly into the lungs – improving tolerability by decreasing systemic exposure and
You have opened 5 full company profiles today. Create an account to keep reading them. Create an account
Key facts
- Headquarters
- Seattle, Washington, United States
- Employees
- 49
- Industries
- Biotechnology, Healthcare, Health Care
- Status
- Public (AVLN)
- Website
- avalynpharma.com
- Company page
Recent activity at Avalyn
- : SEC 8-K (5.02): On September 15, 2026, Avalyn Pharma Inc. appointed Dr. Robert Meyer as a Class II director of the Board, with his term set to expire at the annual meeting of stockholders in 2028. The appointment followed the recommendation of the Nominating and Corporate Governance Committee. Dr. Meyer is considered independent under Nasdaq's listing standards and has a notable background, having been a principal at Greenleaf Health Inc. from January 2018 to October 2024, which is a strategic consulting firm for the FDA. This strategic addition to the Board aims to enhance the company's governance and expertise in regulatory matters.
- : SEC 8-K (1.01): On June 29, 2026, Avalyn Pharma Inc. entered into a First Amendment to the Sublease, which modifies an existing Sublease Agreement with CRISPR Therapeutics, Inc. This amendment expands the leased space from approximately 8,774 to 13,708 square feet at 105 West First Street, Boston, Massachusetts. As a result, the Company’s future minimum lease payments will increase by approximately $924,000 over the remaining lease term. The agreement emphasizes the continuation of the previously established terms of the Sublease Agreement, maintaining its integrity while accommodating the expansion.
- : SEC 8-K (7.01): On June 17, 2026, Avalyn Pharma Inc. announced the completion of target enrollment in the Phase 2b MIST Trial for its product AP01 (Inhaled Pirfenidone), aimed at treating patients with Progressive Pulmonary Fibrosis. The enrollment completion signifies a critical milestone for the trial's progress, which could impact future developments and market potential for AP01 in this therapeutic area. The announcement was made via a press release issued on the same date. No financial amounts were specified in the filing.
About Avalyn: questions and answers
What does Avalyn do?
Avalyn is reimagining the future of pulmonary fibrosis treatment, with a pipeline of new inhaled formulations of approved medicines. Unlike currently available oral therapies, our inhaled approach allows us to tackle the underlying pathophysiology of pulmonary fibrosis at its source by safely delivering treatments directly into the lungs – improving tolerability by decreasing systemic exposure and
Where is Avalyn headquartered?
Avalyn is headquartered in Seattle, Washington, United States.
How many employees does Avalyn have?
Avalyn has about 49 employees.
What is the latest news on Avalyn?
On Sep 15, 2026, SEC 8-K (5.02): On September 15, 2026, Avalyn Pharma Inc. appointed Dr. Robert Meyer as a Class II director of the Board, with his term set to expire at the annual meeting of stockholders in 2028. The appointment followed the recommendation of the Nominating and Corporate Governance Committee. Dr. M
Is Avalyn a public company?
Yes. Avalyn is publicly traded under the ticker AVLN.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy